Works matching AU Deva, Sanjeev

Results: 8

Blending space and time to talk about cancer in extended reality.

Published in:

NPJ Digital Medicine, 2024, v. 7, n. 1, p. 1, doi. 10.1038/s41746-024-01262-x

By:

Robb, Tamsin J.;
Liu, Yinan;
Woodhouse, Braden;
Windahl, Charlotta;
Hurley, Daniel;
McArthur, Grant;
Fox, Stephen B.;
Brown, Lisa;
Guilford, Parry;
Minhinnick, Alice;
Jackson, Christopher;
Blenkiron, Cherie;
Parker, Kate;
Henare, Kimiora;
McColl, Rose;
Haux, Bianca;
Young, Nick;
Boyle, Veronica;
Cameron, Laird;
Deva, Sanjeev

Publication type:

Article

Oral paclitaxel with encequidar compared to intravenous paclitaxel in patients with advanced cancer: A randomised crossover pharmacokinetic study.

Published in:

British Journal of Clinical Pharmacology, 2021, v. 87, n. 12, p. 4670, doi. 10.1111/bcp.14886

By:

Jackson, Christopher G. C. A.;
Hung, Tak;
Segelov, Eva;
Barlow, Paula;
Prenen, Hans;
McLaren, Blair;
Hung, Noelyn Anne;
Clarke, Katriona;
Chao, Tsu‐Yi;
Dai, Ming‐Shen;
Yeh, Hsien‐Tang;
Cutler, David L.;
Kramer, Douglas;
He, Jimmy;
Zhi, Jay;
Chan, Wing‐Kai;
Kwan, Rudolf;
Deva, Sanjeev

Publication type:

Article

Mortality within 30 days of systemic anticancer therapy at a tertiary cancer centre: assessing the safety and quality of clinical care.

Published in:

2017

By:

Wilson, Michelle;
Weng Mak;
Firth, Melissa;
Deva, Sanjeev;
Findlay, Michael;
Mak, Weng

Publication type:

journal article

The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma.

Published in:

Gastric Cancer, 2022, v. 25, n. 5, p. 943, doi. 10.1007/s10120-022-01308-7

By:

Lu, Zhihao;
Yang, Silu;
Luo, Xuerui;
Shi, Yang;
Lee, Jong-Seok;
Deva, Sanjeev;
Liu, Tianshu;
Chao, Yee;
Zhang, Yun;
Huang, Ruiqi;
Xu, Yaling;
Shen, Zhirong;
Shen, Lin

Publication type:

Article

Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study.

Published in:

BMC Cancer, 2014, v. 14, p. 1, doi. 10.1186/1471-2407-14-737

By:

Jackson, Christopher G. C. A.;
Sharples, Katrina;
Thompson, Paul I.;
O'Donnell, Anne;
Robinson, Bridget Anne;
Perez, David J.;
Adams, Jacqui;
Isaacs, Richard;
Deva, Sanjeev;
Hinder, Victoria A.;
Findlay, Michael P.

Publication type:

Article

Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study.

Published in:

2014

By:

Jackson, Christopher Gca;
Sharples, Katrina;
Thompson, Paul I;
O'Donnell, Anne;
Robinson, Bridget Anne;
Perez, David J;
Adams, Jacqui;
Isaacs, Richard;
Deva, Sanjeev;
Hinder, Victoria A;
Findlay, Michael P;
Jackson, Christopher G C A

Publication type:

journal article

Real‐world outcomes of cisplatin, capecitabine, and gemcitabine with either epirubicin (PEXG) or docetaxel (PDXG) as first‐line palliative treatment in metastatic or unresectable locally advanced pancreatic adenocarcinoma.

Published in:

Asia Pacific Journal of Clinical Oncology, 2023, v. 19, n. 5, p. e231, doi. 10.1111/ajco.13845

By:

Hitchen, Nadia;
Waldron, Nick R.;
Deva, Sanjeev;
Findlay, Michael;
Lawrence, Benjamin

Publication type:

Article

Population pharmacokinetics for oral paclitaxel in patients with advanced/metastatic solid tumors.

Published in:

CPT: Pharmacometrics & Systems Pharmacology, 2022, v. 11, n. 7, p. 867, doi. 10.1002/psp4.12799

By:

He, Jimmy;
Jackson, Christopher G. C. A.;
Deva, Sanjeev;
Hung, Tak;
Clarke, Katriona;
Segelov, Eva;
Chao, Tsu‐Yi;
Dai, Ming‐Shen;
Yeh, Hsien‐Tang;
Ma, Wen Wee;
Kramer, Douglas;
Chan, Wing‐Kai;
Kwan, Rudolf;
Cutler, David;
Zhi, Jay

Publication type:

Article